BACKGROUND: Since the last series of guidelines on the management of osteoporosis from Osteoporosis Australia was published in Australian Family Physician (October 2002), there have been further advances in our understanding of the treatment involved in both the prevention of bone loss and the management of established osteoporosis. OBJECTIVE: This article provides updated guidelines for the management of postmenopausal osteoporosis to assist general practitioners identify those women at risk, and reviews current treatment strategies. DISCUSSION: Osteoporosis and its associated problems are major health concerns in Australia, especially with an aging population. While important principles of management are still considered to be maximising peak bone mass and preventing postmenopausal bone loss, new clinical trial data about drugs such as the bisphosphonates, raloxifene and oestrogen have recently become available and the relative role of various agents is gradually becoming clearer. The use of long term hormone therapy has mixed risks and benefits that requires individual patient counselling.
BACKGROUND: Since the last series of guidelines on the management of osteoporosis from Osteoporosis Australia was published in Australian Family Physician (October 2002), there have been further advances in our understanding of the treatment involved in both the prevention of bone loss and the management of established osteoporosis. OBJECTIVE: This article provides updated guidelines for the management of postmenopausal osteoporosis to assist general practitioners identify those women at risk, and reviews current treatment strategies. DISCUSSION: Osteoporosis and its associated problems are major health concerns in Australia, especially with an aging population. While important principles of management are still considered to be maximising peak bone mass and preventing postmenopausal bone loss, new clinical trial data about drugs such as the bisphosphonates, raloxifene and oestrogen have recently become available and the relative role of various agents is gradually becoming clearer. The use of long term hormone therapy has mixed risks and benefits that requires individual patient counselling.
Authors: Miguel Angel Ochoa-Hortal Rull; María Del Carmen Cano-García; Miguel Arrabal-Martín; Miguel Angel Arrabal-Polo Journal: Can Urol Assoc J Date: 2015 Mar-Apr Impact factor: 1.862
Authors: María Sierra Girón-Prieto; Salvador Arias-Santiago; María Del Carmen Cano-García; Antonio Poyatos-Andújar; Tomás de Haro-Muñoz; Felix Abad-Menor; Miguel Quesada-Charneco; Miguel Ángel Arrabal-Polo; Miguel Arrabal-Martín Journal: Int Urol Nephrol Date: 2016-07-04 Impact factor: 2.370